Olaparib – a story of hope for cancer patients 11 Apr 2023 In 1995 researchers at The Institute of Cancer Research, London, uncovered the breast cancer susceptibility gene BRCA2. This discovery helped families to assess their cancer risk through genetic testing, enabling them to be closely monitored or take preventative measures. Find out more Show/Hide
How is genomics transforming cancer research and treatment? Seven lessons learned from the Festival of Genomics & Biodata 2023 06 Feb 2023 Scientists from around the world, including many ICR researchers, gathered last month at the Festival of Genomics & Biodata in London. Julia Bakker and Diana Cano attended the conference and report back on some of the key take-home messages. Find out more Show/Hide
A targeted prostate cancer screening programme could be possible in five years - what will it look like? 28 Jan 2022 The UK began screening for breast cancer nearly 35 years ago but we’re yet to have a screening programme for prostate cancer. Julia Bakker spoke to the UK’s leading expert in prostate cancer genetics, the ICR’s Professor Ros Eeles, about the progress we’re making and when we can expect prostate cancer screening to be a reality. Find out more Show/Hide
ASCO 2021: The science behind olaparib’s promise shown in the OlympiA early breast cancer trial 04 Jun 2021
“Here you really can make a difference” – Professor Chris Lord reflects on the biggest developments in his career so far 18 Oct 2018
ASCO 2017: BRCA-targeting drug olaparib offers hope for women with advanced breast cancer with inherited mutation 07 Jun 2017